东宝生物 (300239.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 2.96B

MomentumView details →

1D Return

−5.50%

YTD Return

−13.14%

RSI (14)

50.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

CNY 2.96B

RSI (14)

50.6

MomentumView details →

1D Return

−5.50%

YTD Return

−13.14%

ProfitabilityView details →

Gross Margin

23.16%

Net Margin

7.35%

EBITDA Margin

21.14%

ROE (TTM)

3.15%

ROA (TTM)

2.14%

Asset Turnover

0.29x

GrowthView details →

Revenue YoY

−10.03%

EPS YoY

−30.02%

FCF YoY

+320.04%

Revenue CAGR 3Y

−7.56%

EPS CAGR 3Y

−20.46%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

4.81x

Quick Ratio

3.05x

Div Yield

0.24%

Div Rate

CNY 0.01

Div Growth 1Y

−52.00%

Financials snapshotView financials →

Revenue (TTM)

747.80M

Net Income (TTM)

54.99M

Op. CF (TTM)

164.39M

Latest newsMore news →

Dongbao Bio, a subsidiary of Guoen Co., Ltd., reported its 2026 semi-annual results: revenue of 415 million yuan, up 12.37% year-on-year; net profit of 37.404 million yuan, up 1.18% year-on-year.5d ago

Similar companies

万得凯301309.SZ 密封科技301020.SZ 泰尔股份002347.SZ 法尔胜000890.SZ 保龄宝002286.SZ 融捷健康300247.SZ Find similar companies →

Latest newsMore news →

Dongbao Bio, a subsidiary of Guoen Co., Ltd., reported its 2026 semi-annual results: revenue of 415 million yuan, up 12.37% year-on-year; net profit of 37.404 million yuan, up 1.18% year-on-year.5d ago